THESEUS PHARMACEUTICALS, INC. Operating Income
THESEUS PHARMACEUTICALS, INC. reported Operating Income of -$16.40 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2023-11-17
- THESEUS PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2023-09-30 was -$16.40M.
- THESEUS PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2023-06-30 was -$17.59M.
- THESEUS PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2023-03-31 was -$17.05M.
- THESEUS PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2022-12-31 was -$15.48M.
- THESEUS PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was -$54.09M.
- THESEUS PHARMACEUTICALS, INC. operating income (loss) for fiscal 2021 was -$27.34M.
- THESEUS PHARMACEUTICALS, INC. operating income (loss) for fiscal 2020 was -$6.84M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$16.40M 10-Q · filed 2023-11-17 | -$33.99M derived: sum of 2 quarters · filed 2023-11-17 | -$51.05M 10-Q · filed 2023-11-17 | -$66.52M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | -$17.59M 10-Q · filed 2023-08-10 | -$34.64M 10-Q · filed 2023-08-10 | -$50.12M derived: sum of 3 quarters · filed 2023-08-10 | -$66.07M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-03-31 | -$17.05M 10-Q · filed 2023-05-11 | -$32.53M derived: sum of 2 quarters · filed 2023-05-11 | -$48.48M derived: sum of 3 quarters · filed 2023-11-17 | -$60.56M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-12-31 | -$15.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$31.43M derived: sum of 2 quarters · filed 2023-11-17 | -$43.51M derived: sum of 3 quarters · filed 2023-11-17 | -$54.09M 10-K · filed 2023-03-09 |
| 2022-09-30 | -$15.95M 10-Q · filed 2023-11-17 | -$28.03M derived: sum of 2 quarters · filed 2023-11-17 | -$38.61M 10-Q · filed 2023-11-17 | -$47.27M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | -$12.08M 10-Q · filed 2023-08-10 | -$22.66M 10-Q · filed 2023-08-10 | -$31.32M derived: sum of 3 quarters · filed 2023-08-10 | -$38.69M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$10.58M 10-Q · filed 2023-05-11 | -$19.24M derived: sum of 2 quarters · filed 2023-05-11 | -$26.61M derived: sum of 3 quarters · filed 2023-05-11 | -$33.43M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$8.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$16.03M derived: sum of 2 quarters · filed 2023-03-09 | -$22.85M derived: sum of 3 quarters · filed 2023-03-09 | -$27.34M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$7.37M 10-Q · filed 2022-11-03 | -$14.19M derived: sum of 2 quarters · filed 2022-11-03 | -$18.68M 10-Q · filed 2022-11-03 | -$21.57M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$6.81M 10-Q · filed 2022-08-11 | -$11.30M 10-Q · filed 2022-08-11 | -$14.19M derived: sum of 3 quarters · filed 2022-08-11 | -$15.62M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$4.49M 10-Q · filed 2022-05-12 | -$7.38M derived: sum of 2 quarters · filed 2022-05-12 | -$8.81M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$4.32M derived: sum of 2 quarters · filed 2022-03-10 | -$6.84M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$1.43M 10-Q · filed 2021-11-15 | -$3.95M 10-Q · filed 2021-11-15 |